πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Clinical Pipeline

First People's Hospital Pipeline

All ClinicalTrials.gov programs at First People's Hospital β€” phase, modality, and trial IDs.

Programs
1,136

Quick answer

First People's Hospital has 1,136 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

  1. KN046

    The First People's Hospital of Lianyungang

    Esophageal Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  2. Kanglaite

    The First People's Hospital of Lianyungang

    Head and Neck Cancer

    phase 2 small molecule completed

    1 trial

  3. LBL-024 for Injection

    The First People's Hospital of Lianyungang

    Triple Negative Breast Cancer

    phase 2 small molecule active

    1 trial

  4. Lanthanum Polystyrene Sulphonate Powder

    The First People's Hospital of Lianyungang

    Hyperphosphatemia

    phase 2 small molecule active

    1 trial

  5. Lenalidomide

    The First People's Hospital of Lianyungang

    PTCL, NOS

    phase 2 small molecule active

    1 trial

  6. Lenalidomide combined with G-CHOP (LO CHOP)

    The First People's Hospital of Lianyungang

    DLBCL - Diffuse Large B Cell Lymphoma

    phase 2 small molecule active

    1 trial

  7. Lenvatinib

    The First People's Hospital of Lianyungang

    Biliary Tract Cancer

    phase 2 small molecule active

    1 trial

  8. Lifei Qingchang Granules

    The First People's Hospital of Lianyungang

    Bronchiectasis

    phase 2 small molecule active

    1 trial

  9. Linperlisib combination with obinutuzumab

    The First People's Hospital of Lianyungang

    Lymphoma

    phase 2 small molecule active

    1 trial

  10. Liposomal irinotecan

    The First People's Hospital of Lianyungang

    Pancreatic Ductal Adenocarcinoma

    phase 2 small molecule active

    1 trial

  11. Liposuction

    The First People's Hospital of Lianyungang

    Anterior Cruciate Ligament Partial Rupture

    phase 2 other active

    1 trial

  12. Luspatercept combined with low-dose thalidomide

    The First People's Hospital of Lianyungang

    Transfusion-dependent Ξ²-thalassemia Patients

    phase 2 small molecule active

    1 trial

  13. MB07133

    The First People's Hospital of Lianyungang

    Safety Issues

    phase 2 small molecule active

    1 trial

  14. MIE

    The First People's Hospital of Lianyungang

    Esophageal Cancer

    phase 2 other active

    1 trial

  15. MenSCs transplantation

    The First People's Hospital of Lianyungang

    Type 1 Diabetes Mellitus

    phase 2 mab active

    1 trial

  16. Menstrual blood stem cells

    The First People's Hospital of Lianyungang

    Acute Lung Injury

    phase 2 small molecule active

    1 trial

  17. Methotrexate tablets

    The First People's Hospital of Lianyungang

    Solid Tumors

    phase 2 small molecule active

    1 trial

  18. Mitoxantrone liposome

    The First People's Hospital of Lianyungang

    Relapsed or Refractory Acute Myeloid Leukemia

    phase 2 small molecule active

    1 trial

  19. NK cell and PD-1 antibody

    The First People's Hospital of Lianyungang

    Non-small Cell Lung Cancer

    phase 2 other completed

    1 trial

  20. Neoadjuvant Chemotherapy (NACT)

    The First People's Hospital of Lianyungang

    HR+/HER2- Breast Cancer

    phase 2 small molecule active

    1 trial

  21. Neoadjuvant Chemotherapy combined with Neoadjuvant Radiotherapy

    The First People's Hospital of Lianyungang

    Breast Cancer

    phase 2 other active

    1 trial

  22. Neoadjuvant Therapy

    The First People's Hospital of Lianyungang

    Gastric Cancer

    phase 2 other active

    1 trial

  23. Neoadjuvant therapy: TCbHPy

    The First People's Hospital of Lianyungang

    Breast Cancer

    phase 2 other active

    1 trial

  24. Nimotuzumab

    The First People's Hospital of Lianyungang

    Esophageal Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  25. Nimotuzumab

    The First People's Hospital of Lianyungang

    Esophageal Neoplasms

    phase 2 small molecule active

    1 trial

  26. Nimotuzumab + SHR-1210

    The First People's Hospital of Lianyungang

    Esophageal Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  27. Nimotuzumab combined with chemoradiotherapy

    The First People's Hospital of Lianyungang

    Pancreatic Cancer Non-resectable

    phase 2 small molecule active

    1 trial

  28. Nintedanib,Dextromethorphan

    The First People's Hospital of Lianyungang

    Idiopathic Pulmonary Fibrosis (IPF)

    phase 2 small molecule active

    1 trial

  29. Nivolumab & Ipilimumab

    The First People's Hospital of Lianyungang

    Lung Cancer - Non Small Cell

    phase 2 small molecule active

    1 trial

  30. Nivolumab Injection [Opdivo]

    The First People's Hospital of Lianyungang

    Neoplasms

    phase 2 small molecule active

    1 trial

  31. OMC and pseudo-SDT

    The First People's Hospital of Lianyungang

    Peripheral Arterial Disease

    phase 2 other completed

    1 trial

  32. Obinutuzumab

    The First People's Hospital of Lianyungang

    Large B-cell Lymphoma

    phase 2 small molecule active

    1 trial

  33. Octacalcium phosphate

    The First People's Hospital of Lianyungang

    Tooth Extraction

    phase 2 other completed

    1 trial

  34. Olverembatinib

    The First People's Hospital of Lianyungang

    Philadelphia-Positive ALL

    phase 2 small molecule active

    1 trial

  35. Olverembatinib

    The First People's Hospital of Lianyungang

    Myeloproliferative Neoplasm

    phase 2 small molecule active

    1 trial

  36. Oral Chinese Herbal Medicine of Clearing heat and Cooling blood therapy

    The First People's Hospital of Lianyungang

    Psoriasis

    phase 2 small molecule active

    1 trial

  37. Orelabrutinib

    The First People's Hospital of Lianyungang

    Marginal Zone Lymphoma(MZL)

    phase 2 small molecule active

    1 trial

  38. Orelabrutinib

    The First People's Hospital of Lianyungang

    Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

    phase 2 small molecule active

    1 trial

  39. Orelabrutinib

    The First People's Hospital of Lianyungang

    Primary Central Nervous System Hodgkin Lymphoma

    phase 2 small molecule active

    1 trial

  40. Orelabrutinib

    The First People's Hospital of Lianyungang

    MALT Lymphoma

    phase 2 small molecule active

    1 trial

  41. Organoid-guided treatment

    The First People's Hospital of Lianyungang

    HER2-negative Breast Cancer

    phase 2 small molecule active

    1 trial

  42. PC-SOD

    The First People's Hospital of Lianyungang

    Myocardial Reperfusion Injury

    phase 2 small molecule active

    1 trial

  43. PCAR-019 (anti-CD19 CAR-T cells)

    The First People's Hospital of Lianyungang

    Acute Lymphocytic Leukemia

    phase 2 mab active

    1 trial

  44. PD -1/PD-L1 monoclonal antibody plus radiotherapy and liver transplantation

    The First People's Hospital of Lianyungang

    Locally Advanced Perihilar Cholangiocarcinoma

    phase 2 other active

    1 trial

  45. PD-1 antibody Sintilimab

    The First People's Hospital of Lianyungang

    Multiple Primary Lung Cancers

    phase 2 small molecule active

    1 trial

  46. PD-1 inhibitor

    The First People's Hospital of Lianyungang

    Advanced NSCLC

    phase 2 small molecule active

    1 trial

  47. PD-1/CTLA-4 Dual Functional Antibody

    The First People's Hospital of Lianyungang

    Bile Duct Carcinoma

    phase 2 small molecule active

    1 trial

  48. PEG-somatropin

    The First People's Hospital of Lianyungang

    Short Stature Children Born Small for Gestational Age (SGA)

    phase 2 mab active

    1 trial

Frequently asked questions

How many pipeline programs does First People's Hospital have?

1,136 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Data attribution: Data sources Β· All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates β€” weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.